Anhui Anke Biotechnology Adjusts Valuation Amidst Growth Challenges and Flat Performance

Anhui Anke Biotechnology (Group) Co., Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently experienced an adjustment in its evaluation. This revision reflects a shift in the company's valuation grade, which has transitioned from a classification of expensive to fair. Key financial metrics indicate a P/E ratio of 18, alongside a price-to-book value of 2.64. The company's enterprise value to EBITDA stands at 13.05, while the dividend yield is noted at 2.31%. Return on capital employed (ROCE) is reported at 23.72%, and return on equity (ROE) is at 14.76%. Despite these metrics, the company has faced challenges in long-term growth, with net sales increasing at an annual rate of 6.52% and operating profit at 11.86% over the past five years. Recent quarterly results have shown flat performance, with net sales and operating profit reaching their lowest points in March 2026. Overall, Anhui Anke Biotechnology's recent evaluation adjustment highlights the complexities of its market position and financial indicators. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.